2024-06-12 16:15:00 ET
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. This means that biotech ETFs allow market participants to gain leverage to many biotech companies via one investment vehicle.
On top of this, the life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.
Below the Investing News Network takes a look at five small cap biotech ETFs for investors to consider. They were selected using ETFdb.com , and their total assets under management (AUM) were under US$100 million as of June 11, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.
For further details see:
5 Small-cap Biotech ETFs to Watch (Updated 2024)